The research landscape around metabolic peptides shifted significantly in June 2023 when Jastreboff and colleagues published the first large-scale human data on retatrutide in The New England Journal of Medicine. The magnitude of the findings — a mean 24.2% reduction in body weight at 48 weeks in the highest-dose cohort — pushed retatrutide ahead of every other incretin-based candidate in the published literature. For investigators in the UAE running metabolic or cardiometabolic research projects, understanding the starter-week titration design is foundational: not just for replicating the trial conditions, but for building a protocol that mirrors the published safety and efficacy profile. This guide covers the triple-agonist mechanism, the evidence-based 2mg ramp-in rationale, reconstitution mathematics for REVIVE LAB UAE's 5mg and 10mg vials, and where to buy retatrutide UAE with HPLC verification and cold-chain dispatch across all seven emirates.
Retatrutide (LY3437943) is a once-weekly injectable peptide agonist that binds three G-protein coupled receptors simultaneously: the glucose-dependent insulinotropic polypeptide receptor (GIPR), the glucagon-like peptide-1 receptor (GLP-1R), and the glucagon receptor (GCGR). This triple-receptor footprint is what separates retatrutide from earlier-generation incretin agents:
The glucagon component is the key differentiator. Glucagon receptor activation in the liver and adipose tissue drives a resting energy expenditure increase that the GLP-1 and GIP arms alone do not produce at comparable doses. In the Jastreboff 2023 NEJM data, the 12mg retatrutide cohort achieved -24.2% body weight at 48 weeks — compared to approximately -15% for semaglutide 2.4mg (STEP-1) and -20.9% for tirzepatide 15mg (SURMOUNT-1) at comparable timeframes. The glucagon lever is why the numbers are bigger. Rosenstock and colleagues (Lancet, 2023) confirmed that the mechanism holds in a type 2 diabetes population, where retatrutide produced HbA1c reductions of up to 2.0 percentage points alongside significant body weight reduction.
In the Jastreboff 2023 NEJM trial, participants were not immediately dosed at 8mg or 12mg. The protocol used a structured escalation beginning at 2mg weekly for the first four weeks. This design choice is pharmacologically deliberate, not arbitrary. Three mechanisms drive the need for a ramp-in phase:
The published escalation sequence from Jastreboff 2023 used a stepwise weekly-dose increase model. For research-context application, the standard ladder investigators reference is:
| Research Week | Weekly Dose | Rationale | Vial Size Used |
|---|---|---|---|
| Weeks 1–4 | 2mg SC once weekly | Starter / GI tolerance phase | 5mg vial (2-dose span) |
| Weeks 5–8 | 4mg SC once weekly | First escalation; receptor ramp | 10mg vial (2-dose span) |
| Weeks 9–12 | 8mg SC once weekly | Second escalation; trial-matching dose | 10mg vial (1-dose span) |
| Week 13+ | 8mg–12mg per protocol | Maintenance / steady-state observation | 10mg vials ongoing |
The 2mg starter week is not a "low activity" phase — at 2mg, retatrutide already engages all three receptors. The published pharmacokinetic data shows mean Tmax around 24 hours post-injection and a half-life of approximately 6 days, meaning the molecule is still active by the time the next weekly dose is administered. Investigators note that even the 2mg phase produces measurable changes in appetite signalling and energy metabolism within the first observation window.
Before ordering any research compound, investigators should understand the primary evidence base. Two landmark publications anchor the retatrutide data:
Jastreboff et al. 2023 — NEJM (TRIPLE-PHARMACOLOGY trial). A 48-week, randomised, double-blind, placebo-controlled phase 2 trial in adults with obesity (BMI ≥27). The 12mg retatrutide weekly cohort achieved a mean body weight reduction of 24.2% from baseline versus 2.1% in placebo. The 8mg cohort achieved -17.3%. The 2mg cohort achieved -8.7% — a meaningful effect even at the lowest research dose. Gastrointestinal adverse events were dose-dependent and most prevalent in the first 4-8 weeks, supporting the starter-week ramp design.
Rosenstock et al. 2023 — The Lancet. A phase 2 trial in type 2 diabetes. Retatrutide at 12mg weekly produced a mean HbA1c reduction of 2.02 percentage points and a body weight reduction of 16.9% at 24 weeks. The study confirmed that the GIP/GLP-1/glucagon triagonist mechanism operates across metabolic disease states — not only in non-diabetic obesity models. Fasting glucose and triglyceride profiles also improved across dose cohorts.
Taken together, these two datasets establish retatrutide as the most potent incretin-class agent yet studied in peer-reviewed, randomised controlled trials. The 2mg starting dose appears in both trial designs as the ramp-in anchor.
REVIVE LAB UAE supplies retatrutide as lyophilized powder in 5mg and 10mg vials. Reconstitution with bacteriostatic water (BAC water) gives researchers precise control over draw volume. Below are the standard reconstitution configurations for the 2mg starter-week dose:
| Vial Size | BAC Water Added | Concentration | Volume for 2mg Dose | Weeks Covered |
|---|---|---|---|---|
| Retatrutide 5mg | 1.0 mL | 5 mg/mL | 0.40 mL (40 IU on insulin syringe) | 2 weeks |
| Retatrutide 5mg | 2.5 mL | 2 mg/mL | 1.00 mL (100 IU on insulin syringe) | 2 weeks |
| Retatrutide 10mg | 2.0 mL | 5 mg/mL | 0.40 mL (40 IU on insulin syringe) | 4 weeks (starter block) |
| Retatrutide 10mg | 5.0 mL | 2 mg/mL | 1.00 mL (100 IU on insulin syringe) | 4 weeks (starter block) |
Most investigators prefer the 5mg/mL concentration (higher-concentration reconstitution) for sub-cutaneous injection to minimise injection volume. Reconstitute by injecting BAC water slowly down the side wall of the vial — never directly onto the lyophilized cake. Swirl gently; do not vortex. Store reconstituted vials at 2-8°C and use within 28 days. Lyophilized vials from REVIVE LAB UAE are stable at 2-8°C through the full labelled shelf life when stored correctly.
Experienced investigators running a retatrutide 2mg starter-week protocol typically confirm the following before initiating the first injection cycle. This checklist mirrors standard research-use best practices, not medical advice:
| Item | Standard | Notes |
|---|---|---|
| Vial purity confirmation | HPLC ≥99%, lot COA on file | Request COA from REVIVE LAB UAE at order |
| Reconstitution environment | Clean surface, alcohol-wiped septum | Use fresh 18G needle to pierce, 27G to draw |
| BAC water sourced | 0.9% benzyl alcohol in sterile WFI | Avoid plain sterile water — shorter stability |
| Storage confirmed | 2-8°C fridge, no freeze-thaw | Away from fridge door; use thermometer |
| Baseline metabolic markers | Fasting glucose, lipids, body weight | Establishes pre-research reference point |
| Protocol timeline mapped | Weeks 1-4 at 2mg, then escalation | Weekly injection same day each week |
| Supply buffer confirmed | At least 2 vials in hand before week 1 | Avoids mid-protocol gap; order from REVIVE LAB UAE |
The supply buffer point deserves emphasis. A mid-protocol stock gap — even for one week — breaks the pharmacokinetic continuity of the research design. Because retatrutide has a ~6-day half-life, a missed week at the 2mg phase is recoverable, but a missed week at 8mg introduces a washout artifact that complicates later data interpretation. When investigators buy retatrutide UAE from REVIVE LAB UAE, retatrutide same day Dubai dispatch means the continuity risk is effectively eliminated for Dubai-based research sites.
REVIVE LAB UAE is a Dubai-based peptides UAE supplier with HPLC-verified lot-COA retatrutide in stock in both 5mg and 10mg vials. Cold-chain dispatch is the standard, not an option. Every order is packed in insulated cold packaging validated to hold 2-8°C through UAE summer courier transit. Retatrutide Dubai 24h delivery covers every emirate; retatrutide same day Dubai delivery applies to all Dubai zones for orders placed before the daily cut-off.
| Emirate / City | Delivery Window | Cash on Delivery | Cold Chain |
|---|---|---|---|
| Dubai (Marina, JBR, Business Bay, DIFC, JVC, Jumeirah, Downtown, Palm, Emirates Hills) | Same-day, 4-8 hours | Yes | Yes |
| Abu Dhabi (Corniche, Yas Island, Saadiyat, Reem Island) | Next-day, 18-24 hours | Yes | Yes |
| Sharjah | Same-day / next-day, 8-18 hours | Yes | Yes |
| Ajman | Next-day, 18-24 hours | Yes | Yes |
| Ras Al Khaimah (RAK) | Next-day, 18-24 hours | Yes | Yes |
| Fujairah | Next-day, 24 hours | Yes | Yes |
| Umm Al Quwain (UAQ) | Next-day, 18-24 hours | Yes | Yes |
| Al Ain | Next-day, 24 hours | Yes | Yes |
Payment options include cash on delivery Dubai (and across all emirates), bank transfer, and USDT TRC20 crypto pay via Binance Pay — researchers who pay in USDT receive a 5% pre-pay discount on their order. All shipments use plain, unbranded outer packaging. COA documents are available on request at point of order — simply specify your lot number preference when placing the order via WhatsApp.
For the broader REVIVE LAB UAE research catalogue — Tesamorelin (GHRH analog), GHK-Cu (copper tripeptide, collagen and tissue remodelling), BPC-157, TB-500, Semax, NAD+, Ipamorelin and MOTS-c — see the full peptides UAE catalogue. The three bestsellers alongside retatrutide are Tesamorelin, GHK-Cu and Retatrutide — all stocked in Dubai now.
REVIVE LAB UAE stocks retatrutide in 5mg and 10mg vials — these are the two stocked strengths. For a standard four-week starter phase at 2mg per week, a single 10mg vial covers the entire 2mg block (four doses of 2mg = 8mg consumed, leaving a small buffer). A 5mg vial covers exactly two weeks at 2mg. Most investigators prefer to order one 10mg vial for weeks 1-4, then a second 10mg vial for the 4mg phase (weeks 5-8, two doses of 4mg = 8mg consumed). Both vials are HPLC-verified, dispatched cold-chain with lot COA.
Yes. REVIVE LAB UAE offers retatrutide same day Dubai delivery for orders before the daily cut-off — typically arriving at Dubai Marina, JBR, Business Bay, DIFC, JVC, Jumeirah, Palm Jumeirah, Downtown and adjacent areas within 4-8 hours. Retatrutide Dubai 24h delivery covers Abu Dhabi, Sharjah, RAK, Ajman, Fujairah and UAQ on a next-day basis. Cash on delivery Dubai and USDT crypto pay are both supported. All packaging is unbranded and discreet.
The Jastreboff et al. 2023 NEJM TRIPLE-PHARMACOLOGY trial used a structured dose-escalation design starting at 2mg weekly to allow characterisation of GI tolerance before higher receptor occupancy. Retatrutide's triagonist mechanism — simultaneous GIP, GLP-1 and glucagon receptor activation — engages three receptor systems with GI expression. The 2mg phase establishes the individual response profile, detects GI sensitivity early, and allows the receptor signalling pathways to adapt before full-engagement doses. Skipping the starter phase forfeits interpretable dose-response data at the individual observation level and increases the risk of protocol discontinuation due to GI adverse events.